Arch Biopartners Stock Probability Of Bankruptcy
| ARCH Stock | CAD 1.94 0.01 0.51% |
Arch | Probability Of Bankruptcy |
Arch Biopartners Company odds of financial turmoil Analysis
Arch Biopartners' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Arch Biopartners Probability Of Bankruptcy | Less than 29% |
Most of Arch Biopartners' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arch Biopartners is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Arch Biopartners probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Arch Biopartners odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Arch Biopartners financial health.
Arch Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Arch Biopartners is extremely important. It helps to project a fair market value of Arch Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Arch Biopartners' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arch Biopartners' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arch Biopartners' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Arch Biopartners has a Probability Of Bankruptcy of 29.0%. This is 33.01% lower than that of the Biotechnology sector and 47.12% lower than that of the Health Care industry. The probability of bankruptcy for all Canada stocks is 27.19% higher than that of the company.
Arch Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arch Biopartners' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arch Biopartners could also be used in its relative valuation, which is a method of valuing Arch Biopartners by comparing valuation metrics of similar companies.Arch Biopartners is currently under evaluation in probability of bankruptcy category among its peers.
Arch Biopartners Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Return On Assets | (6.24) | (0.44) | (1.74) | (2.84) | (2.9K) | (2.8K) | |
| Asset Turnover | 0.0916 | 1.46 | 1.55 | 1.69 | 4.59 | 4.81 | |
| Gross Profit Margin | (31.27) | (0.0385) | (0.52) | (0.065) | 0.2 | 0.21 | |
| Net Debt | 2.7M | 4.7M | 3.9M | 4.2M | 4.8M | 5.1M | |
| Total Current Liabilities | 1.2M | 3.2M | 2.8M | 6.0M | 6.9M | 7.2M | |
| Non Current Liabilities Total | 3.4M | 3.4M | 2.3M | 703.9K | 809.5K | 1.3M | |
| Total Assets | 741.3K | 2.7M | 621.6K | 1.2M | 1.1M | 588.8K | |
| Total Current Assets | 741.3K | 2.7M | 621.6K | 1.2M | 1.3M | 1.4M | |
| Total Cash From Operating Activities | (1.9M) | (3.0M) | (1.1M) | (234.1K) | (210.7K) | (221.2K) |
Arch Fundamentals
| Return On Asset | -0.81 | ||||
| Profit Margin | (1.86) % | ||||
| Operating Margin | (1.39) % | ||||
| Current Valuation | 131.58 M | ||||
| Shares Outstanding | 64.94 M | ||||
| Shares Owned By Insiders | 19.86 % | ||||
| Number Of Shares Shorted | 3.97 K | ||||
| Price To Sales | 91.52 X | ||||
| Revenue | 1.98 M | ||||
| Gross Profit | (502.88 K) | ||||
| EBITDA | (5.24 M) | ||||
| Net Income | (3.33 M) | ||||
| Cash And Equivalents | 72.82 K | ||||
| Total Debt | 5.02 M | ||||
| Current Ratio | 0.32 X | ||||
| Book Value Per Share | (0.10) X | ||||
| Cash Flow From Operations | (234.07 K) | ||||
| Short Ratio | 0.29 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Beta | 1.39 | ||||
| Market Capitalization | 129.88 M | ||||
| Total Asset | 1.17 M | ||||
| Retained Earnings | (28.05 M) | ||||
| Working Capital | (4.81 M) | ||||
| Net Asset | 1.17 M |
About Arch Biopartners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arch Biopartners's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arch Biopartners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arch Biopartners based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.